These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19301031)

  • 41. Diagnostic utility of p63 and α-methyl acyl Co A racemase in resolving suspicious foci in prostatic needle biopsy and transurethral resection of prostate specimens.
    Singh V; Manu V; Malik A; Dutta V; Mani NS; Patrikar S
    J Cancer Res Ther; 2014; 10(3):686-92. PubMed ID: 25313761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
    Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
    Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy.
    Carswell BM; Woda BA; Wang X; Li C; Dresser K; Jiang Z
    Histopathology; 2006 May; 48(6):668-73. PubMed ID: 16681682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.
    Mazzucchelli R; Barbisan F; Tagliabracci A; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Virchows Arch; 2007 Apr; 450(4):371-8. PubMed ID: 17285325
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NKX3.1 as a marker of prostatic origin in metastatic tumors.
    Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
    Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?
    Zhou M; Aydin H; Kanane H; Epstein JI
    Am J Surg Pathol; 2004 Feb; 28(2):239-43. PubMed ID: 15043314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
    Rhodes DR; Sanda MG; Otte AP; Chinnaiyan AM; Rubin MA
    J Natl Cancer Inst; 2003 May; 95(9):661-8. PubMed ID: 12734317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prostate cancer development after transurethral resection of the prostate--histopathological studies of radical prostatectomy specimens].
    Kanno H; Umemoto S; Izumi K; Hasumi H; Osada Y; Ohta J; Mikata K; Tuchiya F
    Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):649-59. PubMed ID: 16768146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues.
    Hameed O; Sublett J; Humphrey PA
    Am J Surg Pathol; 2005 May; 29(5):579-87. PubMed ID: 15832080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
    Noordzij MA; Bogdanowicz JF; van Krimpen C; van der Kwast TH; van Steenbrugge GJ
    J Urol; 1997 Nov; 158(5):1880-4; discussion 1884-5. PubMed ID: 9334622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is atypical adenomatous hyperplasia of the prostate a precursor lesion?
    Zhang C; Montironi R; MacLennan GT; Lopez-Beltran A; Li Y; Tan PH; Wang M; Zhang S; Iczkowski KA; Cheng L
    Prostate; 2011 Dec; 71(16):1746-51. PubMed ID: 21480308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Semen AMACR protein as a novel method for detecting prostate cancer.
    Etheridge T; Straus J; Ritter MA; Jarrard DF; Huang W
    Urol Oncol; 2018 Dec; 36(12):532.e1-532.e7. PubMed ID: 30337219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
    Moul JW; Connelly RR; Perahia B; McLeod DG
    J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
    Rubin MA; Zhou M; Dhanasekaran SM; Varambally S; Barrette TR; Sanda MG; Pienta KJ; Ghosh D; Chinnaiyan AM
    JAMA; 2002 Apr; 287(13):1662-70. PubMed ID: 11926890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The clinicopathologic patterns of prostatic diseases and prostate cancer in Saudi patients.
    Mosli HA; Abdel-Meguid TA; Al-Maghrabi JA; Kamal WK; Saadah HA; Farsi HM
    Saudi Med J; 2009 Nov; 30(11):1439-43. PubMed ID: 19882057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidental carcinoma of the prostate.
    van Andel G; Vleeming R; Kurth K; de Reijke TM
    Semin Surg Oncol; 1995; 11(1):36-45. PubMed ID: 7538693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence.
    Cao D; Kibel AS; Gao F; Tao Y; Humphrey PA
    Am J Surg Pathol; 2010 Jul; 34(7):994-1001. PubMed ID: 20505501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies.
    Vanguri VK; Woda BA; Jiang Z
    Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):365-8. PubMed ID: 16932031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Minute focus of prostate cancer on needle biopsy: correlation with radical prostatectomy specimen.
    Montanari E; Del Nero A; Gazzano G; Mangiarotti B; Bernardini P; Longo F; Cordima G; Itri E
    Arch Ital Urol Androl; 2009 Mar; 81(1):9-12. PubMed ID: 19499751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.